LONDON (AP) — The U.K. government announced Friday that it plans to work with a German biopharmaceutical company to develop vaccines targeting emerging variants of COVID-19 as public health officials call for new tools to keep the virus in check as it mutates. As part of the deal, Tuebingen, Germany-based CureVac said it would supply the U.K. with 50 million doses of the vaccines if they are approved by regulators and that it would manufacture the shots in Britain. The government didn’t say how much it was investing in the project.
